Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04104126 · ClinicalTrials.gov registry record · NA
Blood Flow Restriction Therapy in Achilles Injury
A NA study of Achilles Injuries Tendon, sponsored by NYU Langone Health.
- Recruiting
- Registry status
- NA
- Development phase
- 57
- Enrollment target
- 1
- Study location
NCT04104126: Recruiting NA study of Achilles Injuries Tendon, sponsored by NYU Langone Health.
NCT04104126 is a NA study of Achilles Injuries Tendon that is actively recruiting participants, run by NYU Langone Health. The registered enrollment target is 57 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04104126, a NA study of Achilles Injuries Tendon, is actively recruiting participants, sponsored by NYU Langone Health.
- RECRUITING
- Registry status
- NA
- Development phase
- 57 participants
- Enrollment target
- 1
- Study location
Study Summary
Blood flow restriction (BFR) therapy is a brief and partial restriction of venous outflow of an extremity during low load resistance exercises. It is a safe and effective method of improving strength in healthy and active individuals, recovering from orthopedic pathologies and procedures. This prospective, randomized study will look at the implications this form of treatment has on the rehabilitation of Achilles injuries.
Primary Outcome
Measure in increase of strength in the affected leg measured by Biodex.
Conditions Studied
Interventions
- OTHER Standard of Care Physical Therapy
- OTHER Blood flow restriction
Study Locations (1)
New York
- NYU Langone Health - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 57 participants |
| Start Date | 2021-10-08 |
| Est. Completion | 2026-06-01 |
| Phase | NA |
What NCT04104126 shows while recruiting
NCT04104126 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 57 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (96% lower).
The record links to 1 condition, with Achilles Injuries Tendon appearing as the primary indexed condition, and to 2 interventions - of which Standard of Care Physical Therapy is the first listed.
NCT04104126 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT04104126 about?
NCT04104126 is a clinical study titled "Blood Flow Restriction Therapy in Achilles Injury". Blood flow restriction (BFR) therapy is a brief and partial restriction of venous outflow of an extremity during low load resistance exercises. It is a safe and effective method of improving strength in healthy and active individuals, recovering from orthopedic pathologies and procedures. This prosp...
What is the current status of trial NCT04104126?
This trial is currently recruiting. It is a NA study. The enrollment target is 57 participants. The study started on 2021-10-08. Estimated completion is 2026-06-01.
What conditions does trial NCT04104126 study?
This clinical trial studies the following conditions: Achilles Injuries Tendon.
What interventions are being tested in trial NCT04104126?
The interventions under investigation include: Standard of Care Physical Therapy (OTHER), Blood flow restriction (OTHER).
Who is sponsoring clinical trial NCT04104126?
This trial is sponsored by NYU Langone Health, which has 1,164 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04104126 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04104126's enrollment target sits among peer trials
57 1262nd of 2000 higher than 739 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03521830 · 57 participants · Phase 2
Nivolumab Alone or Plus Relatlimab or Ipilimumab for Patients With Locally-Advanced Unresectable or Metastatic Basal Cell Carcinoma
- NCT03587701 · 57 participants · Phase 2
Effects of Anakinra in Subjects With Corticosteroid-resistant/Intolerant Meniere's Disease and Autoimmune Inner Ear Disease
- NCT04703842 · 57 participants · Phase 1
Modulation of SERCA2a of Intra-myocytic Calcium Trafficking in Heart Failure With Reduced Ejection Fraction
- NCT04731519 · 57 participants · NA
Development of a Recovery Oriented Treatment for Post-Acute Suicidal Episode (PASE) Veterans
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI